Nivolumab is an intravenous drug under development for the management of advanced (Stage IV) NSCLC. The drug acts on specific proteins (receptors) on immune cells, allowing the defence system of the body to decrease the growth of cancer cells. If licensed, Nivolumab in combination with the current standard of care (platinum doublet chemotherapy) may offer an additional treatment option for patients with advanced NSCLC who currently have failed to respond to standard of care chemotherapy alone.
Nivolumab (Opdivo) in combination with platinum
Interventions:
Nivolumab (Opdivo; BMS-936558; ONO-4538)
Indications:
Non-small-cell lung cancer (NSCLC)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2017